Literature DB >> 12422071

Increased detection of 14-3-3 protein in cerebrospinal fluid in Sporadic Creutzfeldt-Jakob Disease during the disease course.

Pierric Giraud1, Anne-Gaëlle Biacabe, Guy Chazot, Roger Later, Olivier Joyeux, Yves Moene, Armand Perret-Liaudet.   

Abstract

Diagnosis of Creutzfeldt-Jakob Disease (CJD) is based on neurological signs associated with characteristic electroencephalographic activity or detection of 14-3-3 protein in cerebrospinal fluid. However, the time course of 14-3-3 protein release during sporadic CJD is unknown. We report two observations in which the level of the detected 14-3-3 protein increased significantly with time. These preliminary cases suggest that there may be an increased release of 14-3-3 protein during the course of CJD as already proven for iatrogenic CJD. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12422071     DOI: 10.1159/000066174

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  3 in total

1.  Detection of CSF 14-3-3 Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated Capillary Western Assay.

Authors:  A Fourier; A Dorey; A Perret-Liaudet; I Quadrio
Journal:  Mol Neurobiol       Date:  2017-05-16       Impact factor: 5.590

2.  Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis.

Authors:  Pascual Sanchez-Juan; Raquel Sánchez-Valle; Alison Green; Anna Ladogana; Natividad Cuadrado-Corrales; Eva Mitrová; Kathrina Stoeck; Theodoros Sklaviadis; Jerzy Kulczycki; Klaus Hess; Anna Krasnianski; Michele Equestre; Danka Slivarichová; Albert Saiz; Miguel Calero; Maurizio Pocchiari; Richard Knight; Cornelia M van Duijn; Inga Zerr
Journal:  J Neurol       Date:  2007-03-25       Impact factor: 4.849

3.  [Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia].

Authors:  J Hort; M Valis; G Waberzinek; R Taláb; L Glossová; M Bojar; M Vyhnálek; D Skoda; J Masopust; P Stourac
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.